Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 3/20 | 0.41 |
| ▸ | F9 | P00740 | 2/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | PLG | P00747 | 1/20 | 0.32 |
| ▸ | PROC | P04070 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 2/20 | 0.32 |
| ▸ | PADI3 | Q9ULW8 | 1/20 | 0.31 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.31 |
| ▸ | PADI2 | Q9Y2J8 | 1/20 | 0.31 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.31 |
| ▸ | GHSR | Q92847 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10198641 | 0.92 | F10 (0.46) | F10F9NOS1PLGPROC | |
| SCHEMBL10260041 | 0.90 | F10 (0.43) | F10F9NOS1PLGPROC | |
| SCHEMBL16284389 | 0.87 | F10 (0.43) | F10F9NOS1PLGPROC | |
| SCHEMBL21591 | 0.75 | HTR7 (0.39) | MAP4K4 | |
| SCHEMBL15244944 | 0.72 | F10 (0.46) | F10NOS1 | |
| SCHEMBL15139083 | 0.72 | F10 (0.47) | F10NOS1FAAHPADI3 | |
| SCHEMBL10198621 | 0.72 | HTR7 (0.47) | MAP4K4 | |
| SCHEMBL15805900 | 0.71 | F10 (0.44) | F10NOS1PLGPROCFAAH | |
| SCHEMBL13400051 | 0.71 | NQO2 (0.43) | — | |
| SCHEMBL16605482 | 0.70 | F10 (0.41) | F10NOS1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120295922-A1 | Compounds For Use In Treatment Of Mucositis | POLYMEDIX, INC. (US) | 2012-11-22 | — | — | US | disclosed |
| US-20100081665-A1 | Anti-Malarial Compounds | CELLCEUTIX CORPORATION | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295922-A1 | Compounds For Use In Treatment Of Mucositis | MUC1, FUT6, MMP8 | F10 2584/4885F9 3235/4885NOS1 2001/4885 |
| US-20100081665-A1 | Anti-Malarial Compounds | AADAC, ME2, HTRA2 | F10 4834/4885F9 4850/4885NOS1 2103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.